Cargando…

Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders

A recent report showed that most pediatric cases of non-eosinophilic esophagitis (EoE) eosinophilic gastrointestinal disorders (EGIDs) (non-EoE EGIDs) are persistent and severe compared with those of EoE, thus requiring further effective therapeutic approaches. In this study, we present the first ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Arakawa, Naoya, Yagi, Hisako, Shimizu, Mariko, Shigeta, Daisuke, Shimizu, Akihiko, Nomura, Shigeru, Takizawa, Takumi, Yamada, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856177/
https://www.ncbi.nlm.nih.gov/pubmed/36671497
http://dx.doi.org/10.3390/biom13010112
_version_ 1784873559934369792
author Arakawa, Naoya
Yagi, Hisako
Shimizu, Mariko
Shigeta, Daisuke
Shimizu, Akihiko
Nomura, Shigeru
Takizawa, Takumi
Yamada, Yoshiyuki
author_facet Arakawa, Naoya
Yagi, Hisako
Shimizu, Mariko
Shigeta, Daisuke
Shimizu, Akihiko
Nomura, Shigeru
Takizawa, Takumi
Yamada, Yoshiyuki
author_sort Arakawa, Naoya
collection PubMed
description A recent report showed that most pediatric cases of non-eosinophilic esophagitis (EoE) eosinophilic gastrointestinal disorders (EGIDs) (non-EoE EGIDs) are persistent and severe compared with those of EoE, thus requiring further effective therapeutic approaches. In this study, we present the first case based on a systematic search of non-EoE EGID for which tolerance to causative foods and histological and symptomatic improvements were achieved following dupilumab administration, after elimination diets and omalizumab and mepolizumab treatments. Driven by this case, we investigated the efficacies of biological treatments in non-EoE EGID cases based on the patient studied herein, and other patients identified in the conducted systematic review. Seven articles, including five different biologics, were reviewed. Both clinical efficacies and impact differences among the targeted molecules are demonstrated in this study. Our findings show that dupilumab may affect mechanisms that can suppress symptoms induced by offending foods that are different from those induced by other biologics as identified in the conducted systematic review. Additional studies are required to address the unmet needs of non-EoE EGID treatments.
format Online
Article
Text
id pubmed-9856177
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98561772023-01-21 Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders Arakawa, Naoya Yagi, Hisako Shimizu, Mariko Shigeta, Daisuke Shimizu, Akihiko Nomura, Shigeru Takizawa, Takumi Yamada, Yoshiyuki Biomolecules Communication A recent report showed that most pediatric cases of non-eosinophilic esophagitis (EoE) eosinophilic gastrointestinal disorders (EGIDs) (non-EoE EGIDs) are persistent and severe compared with those of EoE, thus requiring further effective therapeutic approaches. In this study, we present the first case based on a systematic search of non-EoE EGID for which tolerance to causative foods and histological and symptomatic improvements were achieved following dupilumab administration, after elimination diets and omalizumab and mepolizumab treatments. Driven by this case, we investigated the efficacies of biological treatments in non-EoE EGID cases based on the patient studied herein, and other patients identified in the conducted systematic review. Seven articles, including five different biologics, were reviewed. Both clinical efficacies and impact differences among the targeted molecules are demonstrated in this study. Our findings show that dupilumab may affect mechanisms that can suppress symptoms induced by offending foods that are different from those induced by other biologics as identified in the conducted systematic review. Additional studies are required to address the unmet needs of non-EoE EGID treatments. MDPI 2023-01-05 /pmc/articles/PMC9856177/ /pubmed/36671497 http://dx.doi.org/10.3390/biom13010112 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Arakawa, Naoya
Yagi, Hisako
Shimizu, Mariko
Shigeta, Daisuke
Shimizu, Akihiko
Nomura, Shigeru
Takizawa, Takumi
Yamada, Yoshiyuki
Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders
title Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders
title_full Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders
title_fullStr Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders
title_full_unstemmed Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders
title_short Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders
title_sort dupilumab leads to clinical improvements including the acquisition of tolerance to causative foods in non-eosinophilic esophagitis eosinophilic gastrointestinal disorders
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856177/
https://www.ncbi.nlm.nih.gov/pubmed/36671497
http://dx.doi.org/10.3390/biom13010112
work_keys_str_mv AT arakawanaoya dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders
AT yagihisako dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders
AT shimizumariko dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders
AT shigetadaisuke dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders
AT shimizuakihiko dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders
AT nomurashigeru dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders
AT takizawatakumi dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders
AT yamadayoshiyuki dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders